Below are the financial statements of Sartorius Stedim Biotech, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of EUR | 2024 | 2023 |
|---|---|---|
| Sales revenue | 2,780a | 2,775.5a |
| Cost of sales | -1,573.3a | -1,541.5a |
| Gross profit on sales | 1,206.7a | 1,234a |
| Selling and distribution costs | -479.8a | -448.9a |
| Research and development costs | -144.1a | -129.5a |
| General administrative expenses | -168.7a | -167.1a |
| Other operating income | 37a | 40.7a |
| Other operating expenses | -80.6a | -79.8a |
| Earnings before interest and taxes (EBIT) | 370.6a | 449.5a |
| Financial income | 45.4a | 94.4a |
| Financial expenses | -196.7a | -141.9a |
| Financial result | -151.3a | -47.6a |
| Profit before tax | 219.2a | 401.9a |
| Income taxes | -40.7a | -89.2a |
| Net profit for the period | 178.5a | 312.7a |
| Attributable to | — | — |
| Equity holders of Sartorius Stedim Biotech | 175.1a | 310.3a |
| Non-controlling interest | 3.4a | 2.4a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sartorius Stedim Biotech’s data sources below and access millions more through our Disclosure Search.